Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B

Sang Hoon Ahn, Young Oh Kweon, Seung Woon Paik, Joo Hyun Sohn, Kwan Sik Lee, Dong Joon Kim, Teerha Piratvisuth, Man Fung Yuen, Anuchit Chutaputti, You Chen Chao, Aldo Trylesinski, Claudio Avila

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


Purpose Lamivudine (LAM) resistance is common on lamivudine monotherapy for chronic hepatitis B. This study examined the safety and efficacy of telbivudine (LDT) given with adefovir (ADV) versus ADV monotherapy in patients with chronic, lamivudine-resistant HBV infection. Methods An open-label, 96 week study with planned recruitment of 150 HBeAg-positive, lamivudine-experienced Asian patients with a confirmed YMDD resistance mutation, randomized 1:1 to receive ADV alone or with LDT. The study was terminated early due to difficulty in enrolling monotherapy patients. At termination, 42 patients had received study medication for 8-61 weeks. Due to incomplete enrolment, summary statistics only were prepared, without significance testing. Results A total of 42 patients underwent rescue therapy (switch to ADV or LDT + ADV; n = 21 per group). Median treatment duration was 48 weeks in both groups. HBV DNA changes from baseline were greater in the LDT + ADV arm at all time points (Week 48: -7.4 log10 vs. -4.9 log10 copies/ml), and serum DNA was undetectable (<300 copies/mL) at week 48 in 38.5% (5/13) on LDT + ADV versus 0% (0/9) on ADV monotherapy Two patients (9.6%) on ADV monotherapy experienced virologic breakthrough without evidence of ADV resistance, but none on LDT + ADV; and no confirmed ADV resistance was observed in any on-treatment sample. HBeAg loss occurred in three patients on LDT + ADV and one patient on ADV monotherapy through week 48. Safety profiles were similar between the arms. Conclusion LDT + ADV combination treatment showed better outcomes against lamivudine resistant HBV than ADV alone, with a similar safety profile.

Original languageEnglish
Pages (from-to)696-706
Number of pages11
JournalHepatology International
Issue number4
Publication statusPublished - 2012 Oct

Bibliographical note

Funding Information:
Acknowledgements The authors would like to thank the patients, investigators and study centres for their participation. This manuscript was supported by Novartis Pharma AG, with editorial support by Mechthild Jung, Ph.D. (Novartis Pharma AG) and Nick Fitch, Ph.D. (Articulate Science, London, UK). The authors would also like to thank Delft Diagnostic Laboratory, The Netherlands, for performing the HBV DNA sequencing and resistance analyses described herein.

All Science Journal Classification (ASJC) codes

  • Hepatology


Dive into the research topics of 'Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B'. Together they form a unique fingerprint.

Cite this